Litigation Details for Novo Nordisk Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2021)
✉ Email this page to a colleague
Novo Nordisk Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-12-21 |
| Court | District Court, D. Delaware | Date Terminated | 2023-09-25 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 10,220,155; 10,357,616; 10,376,652; 7,762,994; 8,114,833; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,265,893; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; 9,968,659; RE46,363 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novo Nordisk Inc. v. Teva Pharmaceuticals, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in Novo Nordisk Inc. v. Teva Pharmaceuticals, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Novo Nordisk Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-12-21 | 1 | Complaint | the “’953 patent”), 9,861,757 (the “’757 patent”), 9,968,659 (the “’659 patent”), 10,220,155 (the “’155… COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 10,220,155 107. Novo Nordisk re-alleges… United States Patent Nos. 7,762,994 (the “’994 patent”), 8,114,833 (the “’833 patent”), 8,684,969 (the…(the “’969 patent”), 8,920,383 (the “’383 patent”), 9,108,002 (the “’002 patent”), 9,132,239 (the “’239…’239 patent”), 9,457,154 (the “’154 patent”), 9,616,180 (the “’180 patent”), 9,687,611 (the “’611 patent | External link to document |
| 2023-04-14 | 104 | Notice of Service | Preliminary Invalidity Contentions Regarding U.S. Patent Nos. 8,114,833; 9,101,718; and 9,265,893 - filed by Novo… 25 September 2023 1:21-cv-01782 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-04-28 | 106 | Notice of Service | . Tessier, Ph.D. Regarding Patent Infringement of U.S. Patent No. 8,114,833 and Exhibits A-B; (4) Opening… 25 September 2023 1:21-cv-01782 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-05-01 | 107 | Notice of Service | Robert J. Orr on the Invalidity of U.S. Patent No. 8,114,833 filed by Teva Pharmaceuticals USA, Inc.,…Karl R. Leinsing M.S.M.E., P.E. Invalidity of U.S. Patent Nos. 9,265,893 and 9,101,718 2) Opening Expert … 25 September 2023 1:21-cv-01782 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-05-26 | 108 | Notice of Service | Tessier, Ph.D. Regarding Validity of U.S. Patent No. 8,114,833; (2) Rebuttal Expert Report of Kimberly …Virender Kumar Sarin Regarding Validity of U.S. Patent No. 8,114,833 filed by Novo Nordisk A/S, Novo Nordisk …Ph.D. Regarding Validity of U.S. Patent No. 9,265,893 and U.S. Patent No. 9,101,718; and (3) Rebuttal … 25 September 2023 1:21-cv-01782 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-05-30 | 109 | Notice of Service | Non-Infringement and Obviousness of U.S. Patent No. 8,114,833 3) Rebuttal Expert Report of Ivan T. Hofmann…Report of Karl R. Leinsing, M.S.M.E., P.E. U.S. Patent Nos. 9,265,893 and 9,101,718 2) Expert Report of… 25 September 2023 1:21-cv-01782 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
